|Day's Range||2.5200 - 3.0500|
Altria shares are falling after a report that San Francisco officials are looking into cracking down on Juul. CNBC's Aditi Roy reports.
Vaping products supplier Greenlane Holdings Inc filed for an initial public offering with U.S. regulators on Wednesday, in the backdrop of both growing investor interest and rising regulatory scrutiny into the e-cigarette industry. Greenlane sells vaping products and accessories to over 6,600 independent smoke shops, regional retail stores and a number of licensed cannabis cultivators, processors and dispensaries. Greenlane's move to tap equity markets comes as traditional tobacco companies make major investments into e-cigarettes.
OUTSIDE THE BOX Tobacco stocks got a bounce earlier this month on news of the resignation of Food & Drug Administration chief Scott Gottlieb. This made sense because he has had it in for vaping, menthol cigarettes and nicotine levels in cigarettes.
So far, 2019 has been good to Cronos Group (NASDAQ:CRON). Its share price has more than doubled this year. And the CRON stock gains make some sense.Indeed, as I wrote in December, the $1.8 billion investment in CRON stock by Altria (NYSE:MO) seems to be a game-changer. Among cannabis stocks, only Canopy Growth (NYSE:CGC), with $4 billion in hand from its deal with Constellation Brands (NYSE:STZ), looked to be in a stronger financial position. And yet, amid a market sell-off, investors largely shrugged at Cronos Group stock.That's changed in 2019, obviously, and perhaps it's changed a little too much. I still believe CRON stock needs to settle down. And I'm not alone. Wall Street has turned notably bearish on the shares in recent weeks. Ahead of Cronos Group earnings next week, those analysts might have a point.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cautious Turn on CRON StockAs MarketWatch pointed out last week, the Street on the whole actually sees downside ahead for CRON shares. Some 11 analysts on average have a target price of $20.30, or 6.6% below current levels.And recent coverage hasn't been all that positive. Per MarketWatch, BMO Capital Markets downgraded CRON to underperform. Analyst Tamy Chen pointed out that CRON trades at 80x EBITDA estimates -- two times the multiple sported by Aurora Cannabis (NYSE:ACB) and higher than Canopy Growth.Chen isn't alone. GMP Securities cut Cronos to hold earlier this month. Cowen (NASDAQ:COWN) initiated at neutral. Jefferies Financial Group (NYSE:JEF) began its coverage of Cronos Group stock with an underperform in late February (though CRON stock rose anyway). * Top 7 Service Sector Stocks That Will Pay You to Own Them To be sure, the Street isn't as always right. And even bearish analysts -- including the team at Jefferies -- have pointed to a massive opportunity in both recreational and medicinal cannabis.But for investors looking for the best cannabis play, it's worth noting that the analysts aren't just focused on valuation. BMO has pointed out that Cronos is trailing other Canadian producers in building out capacity. According to Yahoo! Finance, Jefferies cited concerns about when, exactly, Cronos would spend the funds from Altria -- and how much support the tobacco giant would give the pot producer in the early going.While it's easy to dismiss analyst concerns -- and, again, it's far from guaranteed that the Street is correct -- the factors driving the downgrades should be given some consideration. This isn't a case of analysts simply hollering about near-term valuation metrics, or arguing that cannabis stocks represent some sort of bubble.The common thread in recent coverage isn't that Cronos Group is failing or that it has no opportunity. Rather, the worry is that the company isn't moving fast enough in an industry where being a first mover increasingly looks like a key advantage. Earnings and Cronos Group StockIt's not just analysts who are making that point. InvestorPlace contributor Luke Lango made the case last month that Canopy Growth, not Cronos, was the best play in cannabis. One reason: CGC stock is actually cheaper on a per-kilogram basis.That can change if Cronos ramps production and puts its Altria funds to work. So far, however, that hasn't quite been the case. In fact, the company earlier this month swapped its shares of privately held Whistler Medical Marijuana for shares in Aurora Cannabis. That deal highlights the difference between the two companies. * 15 Stocks That May Be Hurt by This Year's Big IPOs Aurora's strategy clearly is to take as many shots at as many opportunities as possible in the shortest amount of time. With that strategy, it's possible that Aurora is taking on too many projects. But in a fluid market (from both a competitive and regulatory perspective), and one with multiple products (recreational, medical, CBD, edibles, etc.), Aurora is trying to gain exposure to as many markets as possible.Cronos doesn't have to take the same path as Aurora. But with the stock near the highs -- and triple late November levels -- it's going to need to show something with earnings next week. That may be discussion of what exactly it plans to do with its $1.8 billion in newly received cash. It may be clarity on Altria's role. (Note that Altria's senior director of corporate strategy is joining Cronos as chief financial officer, perhaps a step in the right direction.) It may be talk of additional M&A, after a huge win on the Whistler deal. (Cronos appears to have invested CAD$4 million [$3 million] in the company - and received C$175 million in Aurora stock.)Whatever it is, with the highest valuation in the cannabis stock, the status quo isn't enough. Cronos needs to post an impressive earnings report next week -- and not just in the numbers. Rather, the company needs to convince investors that it can take advantage of its cash, and put that cash to work to drive growth. It won't be easy - and at these prices, expectations are going to be high.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise Compare Brokers The post Who's Made The Right Call On Cronos Group Stock? Altria or Analysts? appeared first on InvestorPlace.
Anheuser-Busch InBev named Marty Barrington its new chairman and said the CEO of private-equity firm 3G Capital was leaving its board, part of a broader shake-up at the world’s biggest brewer as it struggles ...
Altria made a $12.8 billion investment in the e-cigarette maker late last year. The FDA commissioner has accused Juul and Marlboro-maker Altria executives of reneging on promises they made to help combat teen vaping.
The ongoing cannabis stock craze will likely see another move after Monday's closing bell. That's when Canadian pot conglomerate Tilray (NASDAQ:TLRY) is slated to report its fourth-quarter numbers, perhaps pushing Tilray stock out of the sideways rut it's been in since December.Source: Shutterstock Which direction TLRY ends up moving (if it moves at all) remains in question. While investors will certainly be interested in seeing how much marijuana Tilray sold during the quarter -- recreational marijuana in particular, the real scrutiny will be on company has continued to evolve. For Tilray, Q4 was a period to form partnerships and make acquisitions. The rhetoric about that dealmaking will be the key to overcoming any valuation problems or worries about sustained losses for Tilray stock. Tilray Earnings PreviewFor the quarter ending on December 31st, analysts expect TLRY to report revenue of $15.9 million, although some outside estimates put the figure closer to $18.3 million.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 3 Earnings Reports to Watch Next Week That still won't be enough to pull the young, budding company out of the red though. Those same pros are also calling for a loss of 15 cents per share of Tilray stock -- a modest improvement on the loss of 20 cents per share booked during Q3 of last year.It is a work in progress, as is the case with all cannabis stocks at this time. Actual net profits may still be a distant goal.The industry is making progress to that end, however, with some help from much bigger friends. Pot-Laced PartnershipsConstellation Brands (NYSE:STZ) got the pot-partnership ball rolling in August of last year, via a $4 billion investment in Tilray rival Canopy Growth (NYSE:CGC). Altria Group (NYSE:MO) followed suit in December, making a $1.8 billion investment in Cronos Group (NASDAQ:CRON).Both deals were largely intended to secure a stake in the marijuana market, even without knowing exactly what the future may hold. Though marijuana is now legal in Canada and several U.S. states, it remains illegal at the Federal level in the U.S.The newly-formed partnerships are aiming to innovate new products. Tilray Is Moving SlowerTilray has thus far lagged the innovation and team-up movement. And although the Canadian government legalized cannabis in mid-October, Tilray didn't actually sell any recreational cannabis during the first two weeks it was allowed to do so.Tilray has been busy building its team though. Near the end of last year it acquired licensed producer Natura Naturals at a cost of $26.3 million. And, around that same time it inked distribution deals with the pharmaceutical industry, and has agreed to work with Anheuser Busch Inbev (NYSE:BUD) to create and market cannabis-based drinks. In December of last year, the company rounded out its network with a $317 million purchase of Manitoba Harvest.The Q4 report will be the first to include recreational sales, though it still won't reflect the full revenue potential of Tilray.In that light, investors may want to worry less about Q4 numbers and focus more on how it's piecing together its organization in an increasingly competitive environment. Looking Ahead for Tilray StockThe TLRY story is certainly an exciting one, and undoubtedly cannabis has a bright future. But, it remains to be seen if Tilray has a future that's bright enough to merit its $7.0 billion valuation.More than a few investors don't think it does. As of the most recent look, nearly 25% of the stock's float is held as a short position, meaning nearly four million shares of TLRY are held by traders betting Tilray stock will move lower before it moves higher. * 7 Small-Cap Stocks That Make the Grade Those bets could backfire in a big way though. Should the response to Monday's post-close earnings report be a bullish one, a sharp rise in the price of Tilray shares could cause those short-sellers to panic and buy shares to exit their trade, fanning the bullish flames.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 of the Best Stocks to Buy Under $10 * 7 Single-Digit P/E Stocks With Massive Upside * 7 Best Quantum Computing Stocks Trading Today Compare Brokers The post Why Tilray Stock's Q4 Report Shouldn't Be About Q4 Numbers appeared first on InvestorPlace.
Marijuana stocks face a crucial challenge: How to brand cannabis as marijuana legalization spreads and brings more consumers from the streets into stores.
Will Upward Momentum Continue for Altria and Philip Morris?(Continued from Prior Part)Philip Morris’s valuation multiple As the graph below shows, Philip Morris International’s (PM) valuation multiple has increased since the beginning of 2019.
Will Upward Momentum Continue for Altria and Philip Morris?(Continued from Prior Part)Importance of dividends Dividends smoothen out return volatility for shareholders. Both Altria Group (MO) and Philip Morris International (PM) have a history of
Credibility. Without it, a growing company in a competitive arena is lost. With it, it can be a steamroller.Not that Aurora Cannabis (NYSE:ACB) was lacking credibility, but now that it has activist investor Nelson Peltz on board as an advisor, the budding company has much more than it did. ACB stock jumped 14% on Wednesday, ultimately because the hedge fund manager will help Aurora speak with all the right people that can help take the organization to the proverbial next level.Other reasons were cited for the big jump in Aurora Cannabis stock, and those weren't necessarily wrong. But, it's the sudden jolt of Peltz-related credibility that fueled the move.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd yes, for some investors who still weren't quite convinced, this could be enough of a reason take a shot on Aurora Cannabis stock. Missing PiecesACB been something of an outlier among its pot peers, actually. Canopy Growth (NYSE:CGC) last year attracted Constellation Brands (NYSE:STZ) as a major stakeholder. Cronos Group (NYSE:CRON) is in bed with Altria Group (NYSE:MO) which now owns 45%. Aurora doesn't have a major partner yet. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% The reasons why aren't exactly clear. The Canadian company has as much to offer an aspiring cannabis player as Cronos or Canopy Growth.Those reasons, however, are also now irrelevant. Peltz has already dropped hints that he intends -- as Aurora is tacitly hoping -- to set up deals."I look forward to working with Terry (CEO Terry Booth) and the extended Aurora team to evaluate its many operational and strategic opportunities," Peltz commented in the official statement, adding "including potential engagement with mature players in consumer and other market segments."Cowen analyst Vivien Azer agrees, writing of the news: "Peltz brings a network of relationships with large potential strategic companies that ACB could partner with across medical and consumer applications. In addition, we think ACB will be more patient in partnership selection than its peers, particularly regarding equity investment."Some investors are particularly celebrating the fact that Peltz brings a wealth of experience within the food and consumer goods segment.Trian [Peltz's hedge fund] has been involved with a number of consumer packaged goods companies such as PepsiCo (NASDAQ:PEP), Keurig Dr Pepper (NYSE:KDP), Procter & Gamble (NYSE:PG), Kraft Heinz (NYSE:KHC), Mondelez (NASDAQ:MDLZ), among others, noted GMP Securities consumer goods analyst Martin Landry, who upgraded ACB stock following the announcement. Landry goes on to explain: "We believe he could be instrumental in facilitating discussions with large consumer packaged goods companies."The two upsides are just the tangible manifestations of a much-bigger benefit Peltz brings to the table, however. Credibility (and Motivation)While Altria and Constellation are recognizable brand names, neither are established as dealmakers. They're interest in cannabis is largely self-serving, and their plans for their partnership are limited to the development of cannabis-based products.Not so for Nelson Peltz and Aurora Cannabis. He's a known dealmaker that some companies and many investors like to see get involved, especially when potential value has been locked up for too long.Peltz is also not limited to creating synergy between just two organizations. He's willing and able to establish as many partnership with as many entities as possible, without stirring up concerns that he may be building up his partners' competitors as well. He will be doing that, but at least all partners know where they stand, and that Aurora is looking to become a supplier to multiple customers. There's room for all of them, and Peltz will be able to make introductions ACB couldn't on its own. * 7 Top Stocks to Buy From Goldman Sachs' Secret Portfolio Perhaps more than anything else, however, Peltz wants the same thing existing Aurora Cannabis stock holders want -- for the share price to rise. He's being granted options for up to nearly 20 million shares of ACB stock at $7.74 a share, vested gradually over the next four years.So, Peltz doesn't make any real money unless the stock performs well. Bottom Line for ACB StockDon't misread the message. While this is certainly a big win for Aurora, the company remains a risky proposition for multiple reasons.One of them is that cannabis remains illegal at the federal level in the United States despite widespread state-level legalization. Pot's future, and the future of all its derivatives, is still a bit dazed and confused.There's also the not-so-small reality that cannabis and now cannabis-based products are quickly becoming a commodity, which could crimp margins for the debt-laden Aurora.Nevertheless, if Peltz can pull the right strings -- and he's certainly got strings to pull -- the bullish case for Aurora Cannabis stock is bolstered. It's not a reason in and of itself to buy the shares. But, for investors on the fence about stepping into a position, the hedge-fund player's news may be even bigger than the market realizes.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post Aurora Cannabis, Nelson Peltz Tie-Up is Ultimately About One Thing appeared first on InvestorPlace.
U.S. equities are pausing for breath on Thursday, amid nagging concerns about the fate of U.S.-China trade talks and ongoing woes for Boeing (NYSE:BA) after President Trump grounded the 787 MAX -- becoming the last country to do so after two fatal crashes of similar circumstances in the last five months.The drag on the Dow Jones Industrial Average, of which Boeing is a component, means that index hasn't gone anywhere in over a month. And zooming out further, it hasn't gone anywhere since last summer when the 25,500 level was first crossed in July. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% As investors wait for action, it's a perfect time to be reminded of the allure of dividend stocks which literally pay you to wait. While large-cap, big-tech growth stocks have been getting all the attention in recent years, there is still a place for value-focused dividend stocks. Here are seven dividend stocks to check out:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Philip Morris International (PM)Philip Morris International (NYSE:PM) pays a dividend yield of 5.1%. On a technical basis, it's in clear uptrend territory: 3.5% above its 20-day moving average, 14.4% above its 50-day average, and 9.8% above its 200-day average. Shares were recently upgraded to buy by analysts at UBS, who are looking for a $101 price target.The company will next report results on April 18 before the bell. Analysts are looking for earnings of $1.02 per share on revenues of $6.8 billion. When the company last reported results on February 7, earnings of $1.25 beat estimates by nine cents on a 9.6% decline in revenues. Altria Group (MO)Shares of Altria (NYSE:MO) pay a dividend yield of 5.7%. The stock is on the move but not yet overextended: While above its 20-day and 50-day moving averages, its still below its 200-day average. * 7 Stocks to Buy With High ESG Momentum The company will next report results on April 25 before the bell. Analysts are looking for earnings of 94 cents per share on revenues of $4.6 billion. When the company last reported on January 31, earnings of 95 cents per share matches estimates on a 1.5% rise in revenues. The Williams Companies (WMB)Shares of The Williams Companies (NYSE:WMB) pay a dividend yield of 5.5%. The stock is above all three of its major moving averages, but remains 13.9% below its prior 52-week high. The energy pipeline play is well positioned to take advantage of the infrastructure shortage limiting the blitz of U.S. shale oil and gas activity.The company will next report results on May 1 after the close. Analysts are looking for earnings of 23 cents per share on revenues of $2.3 billion. When the company last reported on February 13, earnings of 19 cents per share missed estimates by five cents. Weyerhaeuser (WY)Weyerhaeuser (NYSE:WY) shares pay a dividend yield of 5.2%. Shares are above their 20-day and 50-day moving averages, but remain more than 14% below their 200-day average and nearly a third below the prior 52-week high. Shares recently enjoyed an upgrade by analysts at BMO Capital Markets and were initiated with a buy rating by analysts at Seaport Global Securities. * Are These 3 Airline Stocks in for a Smooth Flight or More Turbulence? The company will next report results on April 26 before the bell. Analysts are looking for earnings of 12 cents per share on revenues of $1.7 billion. When the company last reported on February 1, earnings of 10 cents per share missed estimates by two cents on a 10.3% drop in revenues. Seagate (STX)Seagate (NASDAQ:STX) shares pay a dividend yield of 5.3%. The company is quickly closing in on its 200-day moving average. Semiconductor and memory stocks have been perking up in recent weeks on reports of lean inventories across the industry and hopes of a resurgence of demand for digital devices as global manufacturing recovers.The company will next report results on May 1 after the close. Analysts are looking for earnings of 71 cents per share on revenues of $2.3 billion. When the company last reported on February 4, earnings of $1.41 beat estimates by 14 cents on a 6.6% drop in revenues. Invesco (IVZ)Invesco (NYSE:IVZ) shares pay a dividend yield of 6.2%. Shares are above both their 20-day and 50-day moving averages, but are still more than 12% below their 200-day average and more than 40% away from their prior 52-week high. Barclays analysts recently highlighted management's ongoing effort to find $475 million in cost savings, which would provide an earnings tailwind. * 15 Stocks Sitting on Huge Piles of Cash The company will next report results on April 25 before the bell. Analysts are looking for earnings of 49 cents per share on revenues of $861.5 million. When the company last reported on January 30, earnings of 44 cents per share missed estimates by 11 cents on an 8.5% drop in revenues. Nielsen Holdings (NLSN)Nielsen Holdings (NYSE:NLSN) shares pay a dividend yield of 5.2%. Shares are on a roll, above all three of their major moving averages as they close in on their prior 52-week high which remains 22% to the upside. The company is enjoying a lift thanks to the surge of television programming -- both over-the-air, cable, and streaming -- and the need for programmers to get solid audience data to make production decisions. Activist investor Elliott Management recently purchased a stake.The company will next report results on April 25 before the bell. Analysts are looking for earnings of 32 cents per share on revenues of $1.6 billion. When the company last reported on February 28 earnings of 28 cents per share missed estimates by 27 ents on a 5.8% drop in revenues.As of this writing, William Roth held no positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post 7 Dividend Stocks to Buy Today appeared first on InvestorPlace.
Tobacco stocks recently took a dive on news of the latest Food and Drug Administration (FDA) hire. Investors sold these stocks off as Health and Human Services (HHS) secretary Alex Azar named National Cancer Institute director Ned Sharpless as the interim head of the FDA.Tobacco stocks had initially risen upon news of the resignation of outgoing FDA head Scott Gottlieb. Gottlieb had wanted to lower nicotine levels in cigarettes and ban menthol cigarettes. Now, with Dr. Sharpless in charge, these initiatives could continue to move forward.However, investors should remember that the Surgeon General's report outlining the dangers of smoking came out in 1964. Despite decreased use of the product in the U.S., tobacco stocks have steadily risen in the 55 years since the release of that report. Moreover, hemp legalization, as well as the full legal status of cannabis in several U.S. states could become a source for profit growth.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best Stocks to Buy for the Bull Market's Anniversary Still, no matter the length of Dr. Sharpless's tenure at the FDA, all tobacco stocks will face regulatory challenges. However, by adapting to the regulatory environment and finding new segments of growth, these tobacco stocks can maintain generous dividends and continue offering returns: Altria (MO)Source: Peyri Herrera via Flickr (Modified)As the owner of the popular Marlboro brand, Altria (NYSE:MO) remains one of the more profitable tobacco stocks. Like its peers, MO stock fell upon the news from the FDA. Given the background of Dr. Sharpless, one has to assume he will continue Dr. Gottlieb's anti-tobacco initiatives.However, I think this will serve as a non-event for MO stock. The equity recovered its post-announcement losses in a day. In my view, that recovery signals that the hire of Dr. Sharpless means the status quo, not further bad news.Profit estimates for this year have fallen from $4.32 per share 90 days ago to $4.20 per share today. However, that is old news. Investors also know that profit growth will average 6.91% per year, over the next five years. While this represents a slowdown from the 11.51% per year growth rate over the previous five years, investors have also priced that news into MO.Meanwhile, the company continues to build new sources of revenue. Altria invested $12.8 billion in electronic cigarette maker Juul. Moreover, with the company's $1.8 billion investment in Cronos (NASDAQ:CRON), cannabis can also serve as a new source of revenue.Even if anti-tobacco initiatives harm their traditional business, Altria appears to keep increasing profits and payouts. The dividend yield currently stands at about 5.7%. This payout has risen for ten straight years. Moreover, investors who have held the stock since 2003 and reinvested the dividends now earn back their original investment every year in dividends alone. Hence, while the tenure of Dr. Sharpless could affect stock price growth, MO stock is still likely to continue to deliver returns. Imperial Brands (IMBBY)Source: Shutterstock Those wanting tobacco stocks free from a harsh U.S. regulatory environment pay turn to Imperial Brands (OTCMKTS:IMBBY). This seller of the popular Kool and Winston brands sells tobacco products in more than 160 countries. It also leads the world in fine-cut tobacco products and serves as the leading seller of cigars in several of its markets.The U.S. accounted for about 21.7% of its revenue in 2018. Although this leaves most of the business outside the confines of the FDA regulation, IMBBY stock has suffered like most tobacco stocks as consumers around the world have increasingly turned away from tobacco.Interestingly, the company itself has followed this anti-tobacco trend. In 2016, IMBBY changed its name from Imperial Tobacco to Imperial Brands to reflect all of its lines of business. Like its major peers, Imperial has moved into e-cigarettes. IMBBY has also entered the cannabis business. In 2018, its subsidiary Imperial Brands Ventures invested in Oxford Cannabinoid. This gave Imperial a stake in the market of cannabis-based medicines.Moreover, Imperial has outperformed its peers in one area--dividends. This year's payout of $3.44 per share takes the yield to about 10%. Although the company cut this payout in 2016, it has risen over time. * 10 Dividend Stock Winners As an equity, IMBBY stock may not see big gains in the near term as slowing tobacco use and FDA regulation weigh on the company. However, the company now seeks to revive its fortunes in cannabis and e-cigarettes. This should leave Imperial Brands well-positioned to continue its generous payouts. Philip Morris International (PM)Source: Shutterstock Of the global tobacco stocks, none stand in a better position to avoid the FDA than Philip Morris (NYSE:PM). This company once acted as the offshore arm of Altria and became a separate firm in 2008. Other than possible issues related to its New York City base of operations, its offshore markets leave the FDA with little power to regulate PM.Philip Morris retains the rights to sell Marlboro and other brands outside of the U.S. However, investors should think of PM stock as more than "non-U.S. Altria." It has also separated itself from other tobacco stocks by stating a desire to leave the tobacco business.The company has invested heavily in its iQOS e-cigarette brand. The company hopes iQOS will satisfy both consumers and regulators to the point that it replaces tobacco. At least so far, PM has also chosen not to enter the cannabis space. CEO Andre Calantzopoulos cited his hopes for iQOS as one reason why.Still, PM stock has behaved like a tobacco equity. Like its peers, it has fallen over the last year. Moreover, it has retained the dividend philosophy of its former parent. PM has increased its payout every year since its founding. This year's dividend of $4.56 per share yields about 5.1%. Predicted growth rates of 5.9% this year and 8.5% in 2020 should help the company fund further payout hikes.It remains unclear whether its iQOS-focused strategy will pay off in the long run. However, the non-U.S. focus protects PM stock from most FDA scrutiny. Moreover, its market positioning and generous dividend should make Philip Morris a long-term winner for income-focused investors.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post 3 Tobacco Stocks That Will Perform Well Despite FDA Regulations appeared first on InvestorPlace.
Will Upward Momentum Continue for Altria and Philip Morris?(Continued from Prior Part)Analysts’ revenue expectations For 2019, analysts are expecting Philip Morris International (PM) to post revenue of $30.68 billion, which represents a rise of
Will Upward Momentum Continue for Altria and Philip Morris?(Continued from Prior Part)Analysts’ revenue estimates Analysts expect Altria Group (MO) to post revenue of $19.85 billion in 2019, which represents a rise of 1.1% from $19.63 billion in
Tobacco company Altria Group (NYSE: MO)'s C$2.4-billion ($1.8 billion) investment in cannabis mega player Cronos Group (NASDAQ: CRON) was completed March 8. Per the agreement, Altria has a warrant by which it can acquire additional ownership over the next four years. Cronos said the investment helps with company financial resources and product development while adding regulatory experience to its leadership.
Will Upward Momentum Continue for Altria and Philip Morris?(Continued from Prior Part)Altria’s EPS growth Altria Group (MO) posted adjusted EPS of $3.99 in 2018, which represents a rise of 17.7% from $3.39 in 2017. The revenue growth, lower
EU Says UK Parliament Is Titanic Voting for Iceberg to Move Parliamentary democracy may have some power, but it can’t tell parliaments outside of itself what to do. In “ruling out” a no deal Brexit yesterday in a vote, chief Brexit negotiator for the European Union, Michel Barnier, has likened it to the Titanic voting […]The post Market Morning: EU Rolls Eyes At UK, FAA Grounds 737, FDA Smashes E-Cigs, Tesla DeLorean On Deck appeared first on Market Exclusive.